Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients
Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients have?
Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients has 54 citations in the OpenAlex counts ScholarIQ stores.
When was Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients published?
Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients has 2017 year in the ScholarIQ index.
What is the open-access status of Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients?
Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients has closed oa status in the ScholarIQ index.
What is the DOI of Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients?
The DOI for Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients is on the source record.
What is the PMID of Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients?
The PMID for Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients is on the source record.
What is the OpenAlex record for Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients?
The OpenAlex for Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients is on the source record.